Form 4: Elanco Animal Health Inc: CEO Jeffrey N. Simmons Reports Acquisition of Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, reports acquiring deferred stock units convertible to common stock or cash.

Summary

• On September 20, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 196.8188 deferred stock units.
• These units represent the right to receive one share of Elanco's common stock or the cash equivalent.
• The transaction price was $14.07 per unit.
• Following the reported transaction, Simmons directly owns 3,504.1413 shares of common stock.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The acquisition of deferred stock units by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Industry Context

Insider transactions are closely monitored in the animal health industry to gauge executive sentiment and potential future performance of companies like Elanco. This transaction is a routine disclosure related to executive compensation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence, as it signals the CEO's continued investment in the company.

Key Dates